Spain In Vivo Cro Market Size & Outlook, 2023-2030

The in vivo cro market in Spain is expected to reach a projected revenue of US$ 328.5 million by 2030. A compound annual growth rate of 8.8% is expected of Spain in vivo cro market from 2024 to 2030.
Revenue, 2023 (US$M)
$182.0
Forecast, 2030 (US$M)
$328.5
CAGR, 2024 - 2030
8.8%
Report Coverage
Spain

Spain in vivo cro market highlights

  • The Spain in vivo cro market generated a revenue of USD 182.0 million in 2023 and is expected to reach USD 328.5 million by 2030.
  • The Spain market is expected to grow at a CAGR of 8.8% from 2024 to 2030.
  • In terms of segment, small molecule was the largest revenue generating modality type in 2023.
  • Large Molecule is the most lucrative modality type segment registering the fastest growth during the forecast period.


In vivo cro market data book summary

Market revenue in 2023USD 182.0 million
Market revenue in 2030USD 328.5 million
Growth rate8.8% (CAGR from 2023 to 2030)
Largest segmentSmall molecule
Fastest growing segmentLarge Molecule
Historical data2018 - 2022
Base year2023
Forecast period2024 - 2030
Quantitative unitsRevenue in USD million
Market segmentationSmall Molecule, Large Molecule
Key market players worldwideIQVIA Holdings Inc, JSR Corp, Taconic Biosciences, Evotec SE, Janvier Labs, Charles River Laboratories International Inc, Icon PLC, Labcorp Holdings Inc, PAREXEL, GemPharmatech, PsychoGenics, Biocytogen, SMO-Group


Other key industry trends

  • In terms of revenue, Spain accounted for 3.9% of the global in vivo cro market in 2023.
  • Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
  • In Europe, Germany in vivo cro market is projected to lead the regional market in terms of revenue in 2030.
  • Spain is the fastest growing regional market in Europe and is projected to reach USD 328.5 million by 2030.

Small molecule was the largest segment with a revenue share of 63.57% in 2023. Horizon Databook has segmented the Spain in vivo cro market based on small molecule, large molecule covering the revenue growth of each sub-segment from 2018 to 2030.


Spain is considered to be a major offshoring & outsourcing country for conducting preclinical & clinical studies, owing to the availability of experienced investigators, established research quality, and a skilled workforce. In addition, approximately 19% of the R&D investment in the country is dedicated to the pharmaceutical industry.

Continuous support from the government has improved the healthcare infrastructure in the country and has accelerated the advancements in R&D. These factors are expected to increase the demand for in vivo CRO services as pharmaceutical companies seek external expertise for their R&D activities. This trend is anticipated to propel market growth during the forecast period.

No credit card required*

Horizon in a snapshot

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more

In Vivo CRO Market Companies

Name Profile # Employees HQ Website

Spain in vivo cro market size, by modality type, 2018-2030 (US$M)

Spain In Vivo CRO Market Outlook Share, 2023 & 2030 (US$M)

Spain in vivo cro market size, by modality type, 2018-2030 (US$M)

Sign up - it's easy, and free!

Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our free plan indefinitely.

Explore all plans

Included in Horizon account

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more